Extract

This study is a Phase 2 randomized, double-blind, double-dummy, parallel-group study designed to assess the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of multiple doses of ABT 122 in subjects with active rheumatoid arthritis (RA) who are inadequately responding to methotrexate (MTX) treatment.

Inclusion criteria

• Rheumatoid Arthritis

Country

• Bulgaria
• Czech Republic
• Germany
• Hungary
• New Zealand
• Poland
• Romania
• United States

Links

• nct
• ictrp